K. J. P. Craib
University of British Columbia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by K. J. P. Craib.
The Lancet | 1994
Robert S. Hogg; Steffanie A. Strathdee; K. J. P. Craib; M. V. O'shaughnessy; J. S. G. Montaner; M. T. Schechter
We studied the association between socioeconomic status and survival in a prospective study of 364 HIV-infected homosexual men who were recruited during 1982-84. The participants were divided by annual income; those earning above Canadian
Sexually Transmitted Infections | 1995
K. J. P. Craib; D. R. Meddings; Steffanie A. Strathdee; Robert S. Hogg; J. S. G. Montaner; M. V. O'shaughnessy; M. T. Schechter
10,000 (high-income; n = 274) and those below
AIDS | 1998
Robert S. Hogg; Amy E. Weber; K. J. P. Craib; Aslam H. Anis; M. V. O'shaughnessy; Martin T. Schechter; Julio S. G. Montaner
10,000 (low-income; n = 90) at recruitment. The latter threshold closely approximated to the poverty level for this population. Low income men were significantly younger than high income men but the groups were similar with respect to baseline CD4 counts, subsequent use of anti-retrovirals and prophylaxis against Pneumocystis carinii pneumonia (PCP), and number of visits attended during follow-up. Subjects were followed for a median of 9.5 years (range 1.8-13.1). By Dec 31, 1993, there were 135 deaths yielding a cumulative mortality rate of mean 45% (SD 4.0) at 11.5 years. Men aged 30 or more at infection had poorer survival than those under 30 (mortality risk ratio 1.56; 95% CI 1.09-2.24; p = 0.015), and longer survival was significantly associated with a higher CD4 count at the earliest seropositive visit. The age-adjusted mortality risk ratio for low income men compared with high income men was significantly increased at 1.63 (95% CI 1.11-2.40; p = 0.013). The significant risk of death for low income men persisted despite adjustment for age at infection, CD4 count, use of zidovudine, dideoxyinosine, and dideoxycytidine, use of PCP prophylaxis, and year of infection. We cannot attribute our findings to income loss as a result of more rapid HIV progression because the same effect was present in people who provided income data before seroconversion. Similarly, our findings are not due to differential access to care because the study was done within the context of a universal health care system, and the two income groups received treatments equally. This finding is consistent with the association of lower socioeconomic status with increased morbidity and mortality observed within large populations and in other diseases.
Aids Care-psychological and Socio-medical Aspects of Aids\/hiv | 2007
C. George; Michel Alary; Robert S. Hogg; Joanne Otis; Robert S. Remis; Benoît Mâsse; Bruno Turmel; Roger LeClerc; René Lavoie; Jean Vincelette; Raymond Parent; Keith C. C. Chan; Steve Martindale; Mary Lou Miller; K. J. P. Craib; Martin T. Schechter
OBJECTIVE--To determine whether certain sexually transmitted diseases are independent risk factors for HIV transmission in a cohort of homosexual men. METHODS--Eligible cases were identified as those who had seroconverted between November 1982 and November 1990. Two persistently HIV-seronegative control participants were randomly selected for each case from all participants who remained seronegative in November 1990. For cases, risk factor data were taken from an index visit which was defined as the first seropositive visit, while for controls these data were obtained from a matched visit which occurred within two months of the index visit for the corresponding case. Mantel-Haenszel methods and logistic regression were used to compare differences in risk factors for seroconversion between cases and controls. RESULTS--A total of 125 cases and 250 controls were eligible for this study. Cases were significantly more likely to have had reported any gonorrhoea (17% versus 6%; OR = 2.94; 95% CI: 1.51-5.73) or syphilis (7% versus 2%; OR = 3.78; 95% CI: 1.33-10.79) than controls during the seroconversion period. Multivariate logistic regression revealed rectal gonorrhoea to be independently associated with risk of seroconversion (odds ratio = 3.18; p = 0.044), whereas urethral gonorrhoea (p = 0.479) and pharyngeal gonorrhoea (p = 0.434) were not after inclusion of rectal gonorrhoea. In addition, the following variables were also shown to exert an independent effect on seroconversion: frequency of anal intercourse, use of illicit drugs, number of male sexual partners, and lack of a post-secondary education. CONCLUSIONS--In this observational study, rectal gonorrhoea was found to be associated with HIV seroconversion after adjustment for a number of HIV risk factors. We cannot rule out that rectal gonorrhoea was not directly associated with HIV infection but rather with other residual lifestyle factors not fully adjusted for in the analysis. However, the relationship with gonococcal involvement of a specific anatomic site lends support to a biological association between gonorrhoea and HIV infection, rather than to alternative non-biologic explanations. Our findings are consistent with previous studies reporting an association between HIV infection and non-ulcerative sexually transmitted diseases. Such a direct association might be explained by postulating that gonorrhoea results in inflamed rectal mucosa and compromised epithelial integrity, thereby predisposing an individual to subsequent HIV infection.
Canadian Medical Association Journal | 1999
Robert S. Hogg; Benita Yip; C. Kully; K. J. P. Craib; M. V. O'shaughnessy; Martin T. Schechter; Julio S. G. Montaner
Objective:To estimate the potential direct cost of making triple combination antiretroviral therapy widely available to HIV-positive adults and children living in countries throughout the world. Methods:For each country, antiretroviral costs were obtained by multiplying the annual cost of triple antiretroviral therapy by the estimated number of HIV-positive persons accessing therapy. Per capita antiretroviral costs were computed by dividing the antiretroviral costs by the countrys total population. The potential economic burden was calculated by dividing per capita antiretroviral costs by the gross national product (GNP) per capita. All values are expressed in 1997 US dollars. Results:The potential cost of making triple combination antiretroviral therapy available to HIV-positive individuals throughout the world was estimated to be over US
JAIDS-J ACQ IMM DEF , 32 (5) 545 - 550. (2003) | 2003
Jonathan Elford; Lorraine Sherr; Philippe Adam; June Crawford; Susan Kippax; Garrett Prestage; Patrick Rawstorne; P. Van De Ven; K. J. P. Craib; Robert S. Hogg; Steve Martindale
65.8 billion. By far the greatest financial burden was on sub-Saharan Africa. The highest per capita drug cost in this region would be incurred in the subregions of Southern Africa (US
The Lancet | 1986
M. T. Schechter; WilliamJ. Boyko; B. Douglas; M. Maynard; Brian Willoughby; Alistair Mcleod; K. J. P. Craib
149) followed by East Africa (US
International Journal of Epidemiology | 1997
Robert S. Hogg; Steffanie A. Strathdee; K. J. P. Craib; M. V. O'shaughnessy; Julio S. G. Montaner; Mauro Schechter
116), Middle Africa (US
Journal of Acquired Immune Deficiency Syndromes | 1995
Robert S. Hogg; J. N. Zadra; C. Chan-Yan; R. Voigt; K. J. P. Craib; J. Korosi-Ronco; J. S. G. Montaner; M. T. Schechter
44), and West Africa (US
Canadian Medical Association Journal | 1994
Robert S. Hogg; M. T. Schechter; Julio S. G. Montaner; Irene L. Goldstone; K. J. P. Craib; M. V. O'shaughnessy
42). In the Americas, subregional data indicated the highest per capita drug cost would be in the Latin Caribbean (US